In this video, health-care analyst David Williamson takes a look at the tremendous success of the Bluebird Bio (NASDAQ:BLUE) IPO. The company increased the size of its initial public offering, and priced shares at $17 -- above the top end of its range -- but that still couldn't contain investor appetite for this stock. Shares shot up 50% on the opening day of trading, and have remained there.
Bluebird doesn't have any products in late stage trials, but its three drug-development programs are extremely intriguing. Is the hype for its shares justified, or is this another sign of a biotech bubble? And would investors possibly be better served taking a look at Bluebird's partner Celgene (NASDAQ:CELG)?
Watch and find out.
Follow David on Twitter: @MotleyDavid.
The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.